# A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

> **NCT05817240** · PHASE1 · COMPLETED · sponsor: **Endeavor Biomedicines, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** taladegib
- **DRUG:** nintedanib

## Key facts

- **NCT ID:** NCT05817240
- **Lead sponsor:** Endeavor Biomedicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-03
- **Primary completion:** 2023-06-11
- **Final completion:** 2023-06-21
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817240, "A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05817240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*